Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Ovarian Cancer

Aliases
advanced ovarian cancer, Advanced Ovarian Cancer, Ovarian Carcinoma, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8

638 clinical trials

678 products

63 drugs

3 abstracts

Product
pembrolizumab
Clinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
CBX-12
Clinical trial
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
KU-0059436
Clinical trial
A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Status: Completed, Estimated PCD: 2008-12-17
Product
SGN-PDL1V
Product
Pembrolizumab
Product
Paclitaxel
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
23ME-00610
Product
Bevacizumab
Product
Docetaxel
Clinical trial
A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)
Status: Recruiting, Estimated PCD: 2027-04-27
Product
REGN5668
Product
Cemiplimab
Product
REGN4018
Product
Sarilumab
Product
CT-0508
Product
vudalimab
Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Terminated, Estimated PCD: 2023-06-02
Product
SGN-STNV
Clinical trial
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-01
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Clinical trial
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Status: Terminated, Estimated PCD: 2022-09-30
Product
XMT-1592
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CDX-585
Clinical trial
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-30
Product
COM902
Product
COM902 in combination with COM701
Clinical trial
A Phase 2, Open-label, Single-arm, Multicenter Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced/Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Fludarabine
Product
Tebotelimab
Product
SGN-ALPV
Clinical trial
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-12-13
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Status: Completed, Estimated PCD: 2023-02-08
Product
UCMYM802
Product
Nanrilkefusp Alfa
Clinical trial
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
CRX100
Product
Cyclophosphamide
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Product
COM902 + COM701
Clinical trial
A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-12-01
Product
E-602
Product
BCA101
Clinical trial
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-31
Product
INX-315
Clinical trial
A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Product
SHR-1921
Clinical trial
An Open-label, Randomized, Controlled, Phase II/III Study of SHR-A1921 With or Without Carboplatin Verus Investigator's Choice of Platinum-based Doublet Chemotherapy in Patients With Recurrent Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-06-15
Product
carboplatin
Clinical trial
Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TRK-950
Product
AMXI-5001
Product
Claudin 18.2 CAR-T
Product
Magrolimab
Product
Avelumab
Product
AO-252
Clinical trial
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Status: Active (not recruiting), Estimated PCD: 2023-09-18
Product
Durvalumab
Product
Olaparib
Clinical trial
A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy
Status: Completed, Estimated PCD: 2020-12-03
Clinical trial
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-28
Product
Niraparib
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Carboplatin+Paclitaxel
Product
margetuximab
Product
LOAd703
Product
[225Ac]-FPI-1434
Clinical trial
Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
Status: Active (not recruiting), Estimated PCD: 2023-08-22
Clinical trial
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Niraparib in Japanese Patients With Platinum-sensitive, Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Achieved CR or PR in the Last Chemotherapy Containing Platinum-based Anticancer Agents
Status: Completed, Estimated PCD: 2019-03-17
Product
IDE-161
Product
BDC-3042
Clinical trial
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Oregovomab
Product
89Zr-DFO-girentuximab
Clinical trial
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-09-26
Clinical trial
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2026-03-01
Product
FPI-1175
Product
CDX-1140
Product
Platinum-based doublet chemotherapy
Clinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Status: Recruiting, Estimated PCD: 2025-12-08
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
COM902 + COM701 + Pembrolizumab
Product
MDNA11
Product
entinostat
Product
avelumab
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Status: Completed, Estimated PCD: 2019-02-21
Product
XMT-1660
Product
BD0801
Clinical trial
A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer.
Status: Active (not recruiting), Estimated PCD: 2023-12-08
Product
Placebo
Product
NGM831 plus Pembrolizumab
Product
Entrectinib
Product
Chemotherapy
Product
FPI-1547
Product
Carboplatin
Clinical trial
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Doxorubicin liposome
Product
CDX-301
Product
Leucovorin
Product
Topotecan
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
SEA-TGT
Product
sasanlimab
Product
Brentuximab vedotin
Product
Irinotecan
Product
cyclophosphamide
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-11-02
Product
Ipilimumab
Product
Nivolumab
Clinical trial
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
Status: Terminated, Estimated PCD: 2023-11-01
Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Recruiting, Estimated PCD: 2024-09-15
Product
ONC-392
Product
gavo-cel
Product
fludarabine
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Product
NC410
Product
Plasmodium immunotherapy
Product
CYH33
Product
Pegylated liposomal doxorubicin
Clinical trial
Clinical Study of Plasmodium Immunotherapy for Advanced Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Status: Terminated, Estimated PCD: 2023-02-15
Product
5-FU
Product
Cisplatin
Product
Ramucirumab
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-07
Product
Gemcitabine
Product
ATRC-101
Clinical trial
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-29
Product
NM21-1480
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-06
Product
VIO-01
Product
Gleolan
Product
Elimusertib
Clinical trial
A Phase 3 Multicenter Study of Gleolan™ (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
olaparib
Product
paclitaxel
Clinical trial
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2011-10-10
Clinical trial
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-24
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
NGM438
Product
Imiquimod
Product
PLD
Product
MAGE-A4ᶜ¹º³²T cells
Clinical trial
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor
Status: Terminated, Estimated PCD: 2022-03-08
Product
Lucitanib
Clinical trial
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of MB1707 in Patients With Advanced Cancer
Status: Withdrawn, Estimated PCD: 2024-11-01
Product
Rucaparib
Product
Sacituzumab govitecan
Product
ATX-101 + Carboplatin + Pegylated liposomal doxorubicin
Product
MB1707
Product
TC-510
Clinical trial
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2023-11-30
Clinical trial
An Open-label Phase 1b Study to Determine the Maximum Tolerated and/or Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib (BAY 1895344) in Combination With PARP Inhibitor Niraparib, in Participants With Recurrent Advanced Solid Tumors and Ovarian Cancer
Status: Terminated, Estimated PCD: 2023-12-01
Product
T3011
Product
NKT3447
Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Clinical trial
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-27
Product
BL-M07D1
Product
Triplet combination of COM902 + COM701 + Pembrolizumab
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-10-14
Clinical trial
A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients With Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens
Status: Completed, Estimated PCD: 2022-12-28
Product
DS-9606a
Clinical trial
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers
Status: , Estimated PCD: 2024-07-01
Product
Mirvetuximab + SL-172154
Product
ADP-A2M4CD8
Product
ADP-A2M4CD8 cells + Nivolumab
Clinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-12-02
Product
CART-TnMUC1
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Pegylated Liposomal Doxorubicin
Product
CD70 CAR-T cells
Clinical trial
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
Status: Recruiting, Estimated PCD: 2025-10-25
Product
[225Ac]-FPI-1434 Injection
Clinical trial
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
lorigerlimab
Product
Vobramitamab
Product
BBI-355
Product
PF-07263689
Product
Sasanlimab
Product
PF-06873600
Clinical trial
PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY
Status: Active (not recruiting), Estimated PCD: 2023-04-05
Product
Endocrine Therapy
Clinical trial
A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)
Status: Recruiting, Estimated PCD: 2026-02-19
Clinical trial
A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2013-01-04
Product
Paclitaxel + Carboplatin
Product
PF-06946860 Placebo
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Status: Recruiting, Estimated PCD: 2026-09-30
Product
Erlotinib
Product
Futibatinib
Clinical trial
A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO ASSESS THE EFFECT OF REPEATED SUBCUTANEOUS ADMINISTRATION OF PF-06946860 ON APPETITE IN PARTICIPANTS WITH ADVANCED CANCER AND ANOREXIA, FOLLOWED BY AN 18-WEEK OPEN-LABEL TREATMENT PERIOD
Status: Completed, Estimated PCD: 2022-04-14
Clinical trial
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Status: Recruiting, Estimated PCD: 2025-12-23
Clinical trial
A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
PF-06946860
Product
COM701
Product
Pamiparib
Clinical trial
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2020-08-24
Product
Axitinib
Clinical trial
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Product
Utomilumab
Product
BLU-222
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Ribociclib
Product
Mirvetuximab soravtansine
Clinical trial
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Status: Completed, Estimated PCD: 2021-03-12
Product
Luveltamab
Clinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
Status: Recruiting, Estimated PCD: 2025-09-01
Product
ATX-101
Product
AZD5363
Clinical trial
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Status: Active (not recruiting), Estimated PCD: 2019-04-26
Clinical trial
A Phase Ⅰ/Ⅱ Study of TTI-622 in Combination With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
Status: Terminated, Estimated PCD: 2024-02-15
Product
ELI-002
Clinical trial
Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Status: Completed, Estimated PCD: 2010-06-30
Product
Matching Placebo
Product
Obinutuzumab
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Clinical trial
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2019-02-19
Product
tocilizumab
Clinical trial
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Recruiting, Estimated PCD: 2028-06-01
Product
A2B694
Product
Talazoparib
Product
CMP 001
Clinical trial
An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-11-05
Clinical trial
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Status: Terminated, Estimated PCD: 2024-03-19
Product
Lorlatanib
Product
Pemetrexed
Product
COM701 with Opdivo
Product
TOS-358
Product
JK08
Product
Pegfilgrastim
Product
GRN-300
Product
Doxorubicin
Product
RO7515629
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-10-17
Product
Naptumomab estafenatox and Durvalumab
Product
XL102
Clinical trial
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Abiraterone
Clinical trial
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Terminated, Estimated PCD: 2012-11-01
Product
Fulvestrant
Product
SGN-B7H4V
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Pegilodecakin
Product
nivolumab
Product
XmAb541
Product
TAK-853
Clinical trial
A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-31
Product
PY314 + Pembrolizumab
Product
Prednisone
Product
AZD5335
Clinical trial
FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.
Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-30
Product
Mirvetuximab
Product
PF04518600
Product
Maplirpacept
Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Product
PC14586
Product
Naptumomab estafenatox
Product
Paclitaxel + Docetaxel + Carboplatin + Cisplatin
Product
FOLFOX
Clinical trial
Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance
Status: Recruiting, Estimated PCD: 2025-06-06
Drug
Atezolizumab
Drug
Tiragolumab
Product
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Clinical trial
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
AMG 794
Clinical trial
Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Status: , Estimated PCD: 2024-12-01
Clinical trial
Phase 1 Study to Assess the Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients With Recurrent Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Lurbinectedin
Product
PF-07260437
Clinical trial
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-09-23
Clinical trial
A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-22
Product
INCB106385
Product
INCMGA00012
Product
MSC-1
Product
OVM-200
Product
COM701 + BMS-986207 + Nivolumab
Product
KHK2866
Product
Gemcitabine + Carboplatin
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
PY314
Clinical trial
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-10-19
Product
Brentuximab Vedotin
Product
AZD2281
Clinical trial
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Status: Recruiting, Estimated PCD: 2026-03-17
Product
NUV-868
Product
gemcitabine/nab-paclitaxel
Product
Claudin 18.2
Product
NT-I7
Product
NM32-2668
Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-31
Product
CD70 CAR-T
Clinical trial
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Status: , Estimated PCD: 2024-12-10
Clinical trial
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.
Status: Active (not recruiting), Estimated PCD: 2024-02-29
Clinical trial
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
Status: Active (not recruiting), Estimated PCD: 2025-06-21
Clinical trial
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
Status: Active (not recruiting), Estimated PCD: 2026-08-10
Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-10-17
Clinical trial
A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Product
Radspherin
Product
SNS-101
Product
Innocell Autologous Cellular Immunotherapy
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Clinical trial
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Status: Active (not recruiting), Estimated PCD: 2024-01-17
Product
Paclitaxel or Docetaxel and Carboplatin or Cisplatin
Product
Capecitabine
Product
Pazopanib
Product
KAND145
Clinical trial
A First-in-human, Single-center, Placebo-controlled, Randomized, Double-blind Study in Healthy Subjects to Evaluate Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam After Oral Single and Multiple Ascending Dosing of KAND145
Status: Completed, Estimated PCD: 2024-04-08
Clinical trial
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Product
AZD5305
Product
DSP-7888
Product
Alpelisib
Clinical trial
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-04-21
Product
SynKIR-110
Clinical trial
A Phase 1 Study of SynKIR-110, Autologous T Cells Transduced With Mesothelin KIR-CAR, in Subjects With Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Status: Recruiting, Estimated PCD: 2026-03-15
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2019-05-17
Product
PF-06940434
Product
PF-06801591
Clinical trial
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-06
Product
MK-4830
Product
Doxorubicin Liposome
Product
Mirvetuximab soravtansine plus Bevacizumab
Clinical trial
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
Status: Recruiting, Estimated PCD: 2027-03-01
Product
PRO1107
Product
cemiplimab
Clinical trial
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
Status: Recruiting, Estimated PCD: 2026-06-21
Clinical trial
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Status: Active (not recruiting), Estimated PCD: 2028-05-30
Product
Abemaciclib
Product
Palbociclib
Product
Luteinizing Hormone-Releasing Hormone Agonists
Product
Inavolisib
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
Dato-DXd
Clinical trial
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Status: Completed, Estimated PCD: 2020-09-09
Product
DKN-01
Product
CM-24 and Nivolumab
Product
CM-24
Clinical trial
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
AVB-S6-500
Product
Sigvotatug Vedotin
Clinical trial
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-11-30
Product
Gemcitabine/carboplatin
Product
SO-C101
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)
Status: Recruiting, Estimated PCD: 2024-07-02
Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2024-01-30
Product
NC762
Clinical trial
A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Product
HS-20089
Product
ART0380
Product
PF-07257876
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-11-15
Product
TORL-1-23
Clinical trial
Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Status: Not yet recruiting, Estimated PCD: 2026-05-26
Product
Prednisolone acetate
Product
Brimonidine Tartrate Ophthalmic Solution
Product
Mirvetuximab Soravtansine
Product
Lubricating Eye Drops
Product
COM902 (RDFE)
Product
Enzalutamide
Clinical trial
A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Status: Completed, Estimated PCD: 2016-04-22
Product
placebo
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Completed, Estimated PCD: 2020-06-16
Product
PF-07820435
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2027-01-31
Product
NXP800
Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib
Status: Completed, Estimated PCD: 2023-03-08
Product
cisplatin
Clinical trial
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Status: Recruiting, Estimated PCD: 2039-04-01
Product
Vigil
Product
Atezolizumab
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
JAB-8263
Clinical trial
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.
Status: Terminated, Estimated PCD: 2012-02-01
Product
TALZENNA
Clinical trial
A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Completed, Estimated PCD: 2022-02-04
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Product
FRα peptide plus Adjuvant (GM-CSF)
Clinical trial
A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy
Status: Terminated, Estimated PCD: 2020-01-15
Product
NGM831 + Pembrolizumab
Clinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-01
Product
VMD-928
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Status: Completed, Estimated PCD: 2023-10-24
Product
Avastin
Product
T- Dxd
Product
Camizestrant
Product
MNPR-101-DFO*-89Zr PET Scan
Product
Innocell
Clinical trial
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Ipatasertib
Product
Cobimetinib
Product
Trastuzumab Emtansine
Product
Giredestrant
Product
Letrozole
Clinical trial
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
XmAb20717
Clinical trial
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Status: Recruiting, Estimated PCD: 2024-11-01
Product
ONM-100
Product
Nivolumab, Nab paclitaxel and Gemcitabine
Product
Nivolumab and Nal-IRI/5-FU/LV
Clinical trial
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Disitamab vedotin
Clinical trial
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Status: Recruiting, Estimated PCD: 2026-05-31
Product
HS-10502
Clinical trial
A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies
Status: Completed, Estimated PCD: 2017-01-24
Product
GEN1047
Clinical trial
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
AB-1015
Clinical trial
A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
TUB-040
Clinical trial
A Single-arm, Phase III Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer With High Expression of Folate Receptor-α
Status: Recruiting, Estimated PCD: 2023-04-30
Product
Epacadostat
Clinical trial
A Phase I Study of the Safety and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2017-05-01
Product
IMNN-001
Product
durvalumab
Clinical trial
Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects With Ovarian Cancer
Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)
Status: Recruiting, Estimated PCD: 2024-08-06
Product
ADCT-301
Product
Adjuvant
Product
CYT-0851
Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Status: Completed, Estimated PCD: 2021-11-16
Clinical trial
A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2018-08-01
Clinical trial
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
Status: Active (not recruiting), Estimated PCD: 2024-12-20
Product
NGM120
Clinical trial
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-15
Product
Chemotherapy + Avelumab followed by Avelumab + Talazoparib
Clinical trial
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)
Status: Terminated, Estimated PCD: 2021-12-22
Clinical trial
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2018-05-14
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Terminated, Estimated PCD: 2012-12-31
Product
Taxane
Clinical trial
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2022-02-08
Product
Cellgram-DC
Clinical trial
A Phase I Clinical Study to Assess the Safety and Tolerability of CD70-targeting CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-17
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-01-25
Clinical trial
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
ST316
Product
TG4050
Clinical trial
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Status: Terminated, Estimated PCD: 2020-08-24
Clinical trial
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer
Status: Completed, Estimated PCD: 2021-12-07
Clinical trial
Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)
Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Status: Recruiting, Estimated PCD: 2023-12-31
Product
ZN-c3
Clinical trial
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours (Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)
Status: Recruiting, Estimated PCD: 2024-11-01
Product
AZD1775
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Product
CCT303-406
Clinical trial
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-07-27
Product
FT536
Product
Tisotumab Vedotin
Product
BBI503
Clinical trial
A Randomized, Open Label, Multi-centre, Two-treatment, Two-period, Two-sequence, Two-stage, Multiple Dose, Steady-state, Crossover, Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer Under Fasting Condition
Status: Completed, Estimated PCD: 2022-10-20
Product
Tinostamustine
Clinical trial
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Status: Completed, Estimated PCD: 2018-09-19
Product
PLX2853
Clinical trial
A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies With a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Status: Terminated, Estimated PCD: 2022-04-25
Product
IL-2
Product
AMXT1501
Product
DFMO
Clinical trial
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-31
Product
QBS10072S
Clinical trial
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07224826, AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Withdrawn, Estimated PCD: 2026-04-14
Clinical trial
A Phase Ib/II Clinical Study on the Safety, Pharmacokinetic Characteristics, and Preliminary Efficacy of SC0191 Combination Chemotherapy in Patients With Advanced Ovarian Cancer.
Status: Not yet recruiting, Estimated PCD: 2025-08-30
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Status: Terminated, Estimated PCD: 2023-09-08
Product
Veliparib
Clinical trial
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2019-05-03
Product
cabozantinib
Product
atezolizumab
Product
Cetuximab
Product
Amivantamab
Product
LXH254
Clinical trial
A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations
Status: Terminated, Estimated PCD: 2022-02-18
Product
Zirabev
Clinical trial
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Status: Recruiting, Estimated PCD: 2024-01-31
Product
AK112
Product
E7449
Clinical trial
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2015-07-01
Product
KAND567
Clinical trial
KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1, Open-label, Dose Finding Study of NI-1801, a Bispecific Mesothelin x CD47 Engaging Antibody, in Patients With Mesothelin Expressing Solid Cancers
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women
Status: Active (not recruiting), Estimated PCD: 2021-10-31
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
Tilvestamab
Product
CUE-102
Product
Nirogacestat
Clinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-01-01
Product
Etrumadenant
Product
Zimberelimab
Clinical trial
A Phase I, Multi-center Study to Determine the Effect of Fluzoparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, Repaglinide and Bupropion in Patients With Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2022-10-26
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
AL3818
Clinical trial
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Avutometinib
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Neoantigen specific TCR-T cell
Clinical trial
Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-15
Product
PRGN-3005
Product
Selinexor
Clinical trial
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Status: Completed, Estimated PCD: 2019-05-22
Clinical trial
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
Aldesleukin
Product
TSR-042
Product
SL-172154
Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Status: Completed, Estimated PCD: 2021-10-14
Product
AsiDNA
Clinical trial
A Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
PF-07104091
Product
PF-07104091 + Palbociclib + Fulvestrant
Product
PF-07104091 + Palbociclib + Letrozole
Product
XmAb®22841
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Status: Completed, Estimated PCD: 2023-02-16
Clinical trial
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2021-05-26
Product
ENB003
Clinical trial
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-12-08
Clinical trial
An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
Status: Terminated, Estimated PCD: 2022-05-10
Clinical trial
Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status: Completed, Estimated PCD: 2022-02-02
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2021-01-08
Clinical trial
PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY
Status: Recruiting, Estimated PCD: 2025-01-07
Product
PF-07104091 + Fulvestrant
Product
PF-0704091 + Fulvestrant
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-31
Product
Farletuzumab
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Single-arm, Multicenter, Phase II Clinical Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response
Status: Completed, Estimated PCD: 2010-03-26
Product
NGM707
Clinical trial
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Status: Completed, Estimated PCD: 2018-02-28
Product
BT5528
Clinical trial
An Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors
Status:
Product
NGM707 plus Pembrolizumab
Product
IVX037
Product
2X-121
Product
RAIN-32
Product
OATD-02
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Clinical trial
BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions
Status: Active (not recruiting), Estimated PCD: 2021-10-31
Clinical trial
A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA
Status: Completed
Clinical trial
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
Status: Completed, Estimated PCD: 2018-04-26
Clinical trial
A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Status: Recruiting, Estimated PCD: 2024-03-29
Product
Lynparza (Olaparib)
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Status: Terminated, Estimated PCD: 2017-01-02
Clinical trial
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
Status: Terminated, Estimated PCD: 2020-09-10
Clinical trial
Phase Ib/II Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody (AK112) Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Status: Terminated, Estimated PCD: 2022-06-10
Clinical trial
Zedula Special Drug Use Observational Study "Ovarian Cancer"
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Status: Completed, Estimated PCD: 2021-07-01
Product
IPI-549
Clinical trial
A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer
Status: Completed, Estimated PCD: 2016-08-08
Product
SC0191
Product
Nanoparticle Albumin-bound Paclitaxel
Clinical trial
A Randomized, Multi-center, Cross-over, Comparative Bioavailability Study of DOXIL/CAELYX Manufactured at a New Site in Patients With Advanced or Refractory Ovarian or Breast Cancer
Status: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance
Status: Completed, Estimated PCD: 2023-02-17
Product
AZD 1775
Product
PDR001
Clinical trial
Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Patients
Status: Terminated, Estimated PCD: 2022-06-27
Clinical trial
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.
Status: Not yet recruiting, Estimated PCD: 2025-05-16
Product
NI-1801
Clinical trial
CLINICAL STUDY OF A SINGLE-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND BIODISTRIBUTION OF TECHNETIUM Tc 99m EC20 IN NORMAL VOLUNTEERS AND OVARIAN CANCER PATIENTS
Status: Completed
Clinical trial
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1
Status: Completed, Estimated PCD: 2023-06-01
Product
Ulixertinib
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Clinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-11-28
Product
Oxaliplatin
Product
5-Fluorouracil
Clinical trial
A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)
Status: Not yet recruiting, Estimated PCD: 2025-11-15
Product
Systemic Treatment
Product
AMT-151
Clinical trial
A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-29
Product
Standard of care
Product
Dostarlimab-Placebo
Product
Niraparib-Placebo
Product
AZD8205
Product
SNB-101
Clinical trial
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Status: Terminated, Estimated PCD: 2022-10-17
Product
navicixizumab+paclitaxel
Product
navicixizumab+irinotecan
Product
Seribantumab
Product
chiauranib
Product
NIR178
Clinical trial
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2020-12-03
Clinical trial
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor
Status: Completed, Estimated PCD: 2019-03-01
Product
Lenvatinib
Product
Botensilimab
Product
Balstilimab
Product
SKB264
Clinical trial
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Navicixizumab
Product
niraparib
Clinical trial
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Status:
Product
AdV-tk + Valacyclovir
Product
Chemotherapy + Bevacizumab
Product
STRO-002
Clinical trial
A Multi-cohort, Randomized, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AL2846 Capsules in Treated Subjects With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy
Status: Completed, Estimated PCD: 2020-10-02
Clinical trial
A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Status: Completed, Estimated PCD: 2015-12-01
Product
AL2846
Product
Vigil™
Product
Upifitimab
Product
Toripalimab
Product
ILB-2109
Clinical trial
Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Status: Completed, Estimated PCD: 2017-04-01
Clinical trial
A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2024-09-01
Product
GL-ONC1
Clinical trial
A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Status: Completed, Estimated PCD: 2019-11-05
Product
Imx-110
Clinical trial
A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-10-31
Product
BR55
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Status: Completed, Estimated PCD: 2022-02-08
Product
Tc 99m EC20
Product
AVM0703
Clinical trial
AVM0703-EAP
Status:
Product
CDX-527
Product
Hydrocortisone
Product
Proton pump inhibitor
Product
CX-2009
Product
PF-07209960
Product
ELENAGEN
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Status: Terminated, Estimated PCD: 2022-05-16
Product
PF-07224826
Clinical trial
Open Label Randomized Clinical Study of Plasmid Encoding p62/SQSTM1 (ELenagen) in in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Product
Alectinib
Clinical trial
A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Status: , Estimated PCD: 2004-08-01
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Product
adavosertib
Product
[225Ac]-FPI-1966
Product
[111In]-FPI-1967
Product
vofatamab
Product
ASP0739
Product
KVA12123
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Status: Completed, Estimated PCD: 2018-01-25
Product
DOXIL/CAELYX
Product
AST-201
Product
rhuGM-CSF
Product
EP0057
Product
INCB001158
Clinical trial
A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Product
KVA12123 Plus Pembrolizumab
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status: Completed, Estimated PCD: 2021-08-18
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-08
Product
CPI-006
Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Status: Completed, Estimated PCD: 2022-12-28
Product
TJ004309
Product
APG-2449
Product
CPI-006 + Pembrolizumab
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)
Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
UTD1
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
Platinum-based doublet
Clinical trial
A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin
Status: Completed, Estimated PCD: 2019-01-31
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174
Clinical trial
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Drug
cyclophosphamide
Product
TBI-1301
Clinical trial
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Drug
LY3537982
Clinical trial
A Phase I/II, Open-label, Two-arm, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Relapsed/Refractory Ovarian Cancer
Status: Completed, Estimated PCD: 2022-05-22
Product
Manganese Chloride
Drug
Abraxane
Product
Platinum chemotherapy
Drug
PD-1 antibody
Clinical trial
A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian Cancer
Status: Withdrawn, Estimated PCD: 2025-12-01
Product
Alpha-type-1 Polarized Dendritic Cells
Clinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070
Drug
Gemcitabine
Clinical trial
A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Follicle Stimulating Hormone Receptor T Cells
Product
Autologous Natural Killer Cell-like CTLs
Drug
Entrectinib
Product
Eribulin
Product
Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Clinical trial
Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)
Status: Recruiting, Estimated PCD: 2028-02-01
Drug
AN0025
Clinical trial
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Minoxidil
Clinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Not yet recruiting, Estimated PCD: 2028-06-30
Product
Cabozantinib
Clinical trial
MT2021-27 Intraperitoneal FT538 With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: , Estimated PCD: 2026-09-30
Product
FT538
Drug
Enoblituzumab
Clinical trial
Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Re-stimulated TILs
Drug
IL-2
Drug
FOLFOXIRI
Clinical trial
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Recurrent or Persistent Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Status: Recruiting, Estimated PCD: 2025-11-01
Drug
Sacituzumab govitecan
Clinical trial
A Randomized Double Blind, Multicenter Trial to Assess Time-interval Between Cytoreductive Surgery and Adjuvant Chemotherapy After Administration of Local Anesthetic Intraperitoneally/Perioperatively in Advanced Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-01-10
Product
Ropivacaine
Product
Saline
Clinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-05-09
Clinical trial
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status: Completed, Estimated PCD: 2019-05-15
Drug
carboplatin
Drug
paclitaxel
Clinical trial
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-01
Product
LY4170156
Clinical trial
An Early Phase Randomized Trial of APX005M in BRCAwt Patients With Recurrent Ovarian Cancer
Status: Withdrawn, Estimated PCD: 2023-09-07
Product
APX005M
Clinical trial
GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)
Status: Recruiting, Estimated PCD: 2033-08-01
Drug
Cisplatin
Clinical trial
Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Phase 2 Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Patients With Metastatic Advanced Stage Ovarian Cancer
Status: Recruiting, Estimated PCD: 2026-05-31
Product
HCW9218
Clinical trial
A Phase II Trial Comparing Quality of Life After HIPEC in Patients With Stage IIIC and IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Completed, Estimated PCD: 2024-01-31
Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Product
Sapanisertib
Clinical trial
Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2012-08-01
Product
Carcinoembryonic antigen-expressing measles virus
Product
oncolytic measles virus encoding thyroidal sodium iodide symporter
Clinical trial
Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2026-08-30
Drug
IMNN-001
Product
Reverse transcriptase polymerase chain reaction
Clinical trial
The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies
Status: Terminated, Estimated PCD: 2020-12-31
Drug
PEG-rhG-CSF
Drug
Trastuzumab
Clinical trial
A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2026-12-31
Drug
Adavosertib
Clinical trial
A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-03-10
Product
Fluzoparib
Clinical trial
A Phase 1 Study of Autologous Activated T-cells Targeting the B7-H3 Antigen in Subjects With Recurrent Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Product
CAR.B7-H3
Product
Vemurafenib
Clinical trial
NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-22
Clinical trial
NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Status: Completed, Estimated PCD: 2021-10-19
Clinical trial
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
Homologous Recombination Deficiency
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Dostarlimab
Product
fluzoparib
Clinical trial
Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-05-03
Product
Enapotamab vedotin
Product
TH1902
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Status: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001
Clinical trial
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies
Status: Terminated, Estimated PCD: 2021-07-30
Product
LCL161
Clinical trial
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Rimiducid
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Drug
Tivozanib
Clinical trial
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2020-12-02
Product
Tremelimumab
Clinical trial
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery
Status: Recruiting, Estimated PCD: 2027-02-01
Product
Bevacizumab-Awwb
Clinical trial
Systems Oncology Approach to Optimize Ovarian Cancer Treatment
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Biomolecular profiling
Clinical trial
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Product
Vinorelbine
Product
Vismodegib
Clinical trial
A Phase 1/1b Clinical Trial of Niraparib and Neratinib in Advanced Solid Tumors With an Expansion Cohort in Platinum-resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-05-31
Product
Neratinib
Clinical trial
A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2021-01-30
Product
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Clinical trial
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Recruiting, Estimated PCD: 2028-06-30
Drug
Tegavivint
Clinical trial
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-09-30
Product
NM1F
Clinical trial
A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Status: Recruiting, Estimated PCD: 2026-12-28
Clinical trial
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Status: Recruiting, Estimated PCD: 2027-08-01
Product
HIPEC
Clinical trial
Phase II Study to Assess the Efficacy of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (The ANALLISA Study)
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2021-10-15
Product
Atezolizumab + Avastin + Platinum-based chemotherapy
Product
Placebo + Avastin + Platinum-based chemotherapy
Clinical trial
A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Status: Completed, Estimated PCD: 2022-12-29
Clinical trial
A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Belinostat
Product
Pegylated GCSF
Clinical trial
A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies
Status: Completed, Estimated PCD: 2021-10-15
Clinical trial
Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting - a Phase 2, Single-arm Trial (NEOPRIMA Trial)
Status: Completed, Estimated PCD: 2023-10-01
Product
CPI-0209
Product
Pertuzumab
Drug
Melphalan
Clinical trial
Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial
Status: Recruiting, Estimated PCD: 2024-06-01
Drug
Regorafenib
Clinical trial
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Status: Completed, Estimated PCD: 2023-08-08
Product
Trabectidin
Clinical trial
A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas
Status: Completed, Estimated PCD: 2021-08-03
Product
filgrastim
Product
Therapeutic autologous lymphocytes
Clinical trial
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Status: Completed, Estimated PCD: 2022-05-01
Clinical trial
The Efficacy of T-regulatory Cell Depletion With E7777 Combined With Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study
Status: Recruiting, Estimated PCD: 2025-12-01
Product
E7777
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Status: Active (not recruiting), Estimated PCD: 2015-12-01
Clinical trial
ATP7A Transporter as Biomarker for Predicting Chemoresistance of Serous Ovarian Cancer
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
A Phase II, Single-Arm Trial Assessing Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer: Dose Escalation
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Fluzoparib+Apatinib
Clinical trial
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2024-03-26
Product
MOv19-BBz CAR T cells
Clinical trial
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
An International Retrospective Observational Study Comparing Primary Cytoreductive Surgery With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Patients With Carcinoma of the Ovary, Fallopian Tubes and Peritoneum
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Neoadjuvant chemotherapy
Clinical trial
Non-Randomized, Open-Label, Prospective Phase II Trial to Better Characterize the Status of HRD Leading to a Benefit From Olaparib in Combination With Bevacizumab in Patients With Advanced FIGO Stage III-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First-Line Treatment
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Erdafitinib in Metastatic Steroid-cell Tumor of the Ovary, NOS
Status: Completed, Estimated PCD: 2022-08-22
Product
Erdafitinib
Clinical trial
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
Indocyanine green dye
Clinical trial
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2017-11-10
Clinical trial
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Drug
Pamiparib
Clinical trial
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Status: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
An Open, Multicenter, Exploratory Clinical Study of Fluzoparib in Combination With Bevacizumab for Maintenance Therapy After First-line Platinum-containing Chemotherapy in BRCA Wild-type Advanced Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-01-31
Clinical trial
HRD Tests for Ovarian cancER
Status: Recruiting, Estimated PCD: 2025-06-01
Product
HRD status
Clinical trial
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Alpelisib
Clinical trial
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial
Status: Completed, Estimated PCD: 2020-12-31
Product
IPEC with Cisplatin
Product
Anastrozole
Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184
Clinical trial
Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Sunitinib
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status: Active (not recruiting), Estimated PCD: 2021-02-24
Clinical trial
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Completed, Estimated PCD: 2023-02-01
Clinical trial
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Status: , Estimated PCD: 2025-11-01
Product
NY-ESO-1 Peptide vaccine
Drug
T-VEC
Clinical trial
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Simvastatin
Clinical trial
The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer
Status: Completed, Estimated PCD: 2022-10-31
Clinical trial
Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Atorvastatin
Clinical trial
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Status: Recruiting, Estimated PCD: 2028-12-30
Product
Nilotinib
Clinical trial
A Single-arm, Exploratory Study of Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
Anlotinib
Product
Fuzuloparib
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Status: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration for the Management of Pleural Carcinosis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cisplatine Teva
Clinical trial
EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT
Status: Terminated, Estimated PCD: 2023-04-27
Product
Exemestane
Clinical trial
A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Carboplatin Hyperthermic Intraperitoneal Chemotherapy
Product
Platinum-based systemic chemotherapy
Clinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125
Clinical trial
A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Status: Not yet recruiting, Estimated PCD: 2027-02-01
Product
Tart Cherry Juice
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations.
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: , Estimated PCD: 2025-02-25
Clinical trial
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2029-12-01
Drug
ZEN003694
Clinical trial
Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer
Status: Terminated, Estimated PCD: 2023-10-01
Product
Indocyanine green
Clinical trial
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
Status: Completed, Estimated PCD: 2016-03-10
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Cediranib
Clinical trial
Phase I Dose Escalation Study Evaluating the Safety of Adding Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin-doxorubicin to the Systemic Chemotherapy, and the Recommended Phase II Dose, in Women With Insufficient Response to Carboplatin-paclitaxel for Advanced Epithelial Cancer of the Ovary, Fallopian Tubes or Peritoneum
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Combined PIPAC / IV chemotherapy treatment
Clinical trial
Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment With an Additional Safety and Preliminary Anti-tumor Activity Cohort of Wee-1 Inhibitor AZD1775 Combined With Carboplatin in Patients With Platinum Resistant TP53 Mutated Epithelial Ovarian Cancer
Status: Completed, Estimated PCD: 2023-04-01
Product
MK-1775 + Carboplatin
Clinical trial
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Product
Batiraxcept
Clinical trial
BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Poly ICLC
Clinical trial
A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Status: Recruiting, Estimated PCD: 2031-06-15
Drug
interleukin-2
Drug
fludarabine
Product
KRAS TCR-Transduced PBL
Product
GRT-C903/GRT-R904
Clinical trial
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-30
Product
TSC-203-A0201
Clinical trial
A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies
Status: Not yet recruiting, Estimated PCD: 2029-11-01
Product
UCB4594
Product
TSC-201-B0702
Product
TSC-204-A0201
Product
TSC-204-C0702
Clinical trial
Pilot Trial of Humanized 3S193 Monoclonal Antibody (hu3S193) in Presurgical Patients With Ovarian Cancer
Status: Terminated, Estimated PCD: 2002-02-26
Product
Monoclonal antibody hu3S193
Product
TSC-200-A0201 + TSC-204-A0101
Product
TSC-200-A0201 + TSC-201-B0702
Product
TSC-203-A0201 + TSC-201-B0702
Clinical trial
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
Status: Active (not recruiting), Estimated PCD: 2024-11-02
Drug
mFOLFOX6
Clinical trial
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-27
Product
Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Clinical trial
Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-15
Product
Olaparib + Durvalumab + UV1
Clinical trial
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Status: Terminated, Estimated PCD: 2011-12-01
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Afatinib
Clinical trial
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2022-08-09
Product
Fostamatinib + Paclitaxel
Clinical trial
Next Generation Precision Imaging for Cancer Immunotherapy: Dynamic Nuclear Polarization and Metabolomics Study
Status: Not yet recruiting, Estimated PCD: 2026-07-31
Product
Hyperpolarized 13C-Pyruvate
Clinical trial
The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Clinical trial
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-02
Product
LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Clinical trial
Triweekly Chemotherapy With Bevacizumab Versus Intraperitoneal Chemotherapy as Frontline Therapy in Advanced Ovarian Cancer
Status: Completed, Estimated PCD: 2023-05-01
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-08-19
Product
Datopotamab deruxtecan
Drug
Saruparib
Clinical trial
First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients
Status: Recruiting, Estimated PCD: 2025-04-01
Product
IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
Clinical trial
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer
Status: Recruiting, Estimated PCD: 2027-03-23
Product
Rilvegostomig
Clinical trial
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
Status: , Estimated PCD: 2024-09-24
Clinical trial
A Phase 1 Dose Escalation of ArtemiCoffee in Patients With Advanced Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Artemisia annua
Clinical trial
Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
3 cycles of standard chemotherapy
Clinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer: A Single-arm, Single-center, Exploratory Clinical Study
Status: Recruiting, Estimated PCD: 2025-05-01
Product
METR-NK
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
AB598
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
doxorubicin
Drug
fluorouracil
Clinical trial
A Phase 2 Study of Zafirlukast for the Treatment of Tumor-marker Only Relapsed Ovarian Cancer
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Zafirlukast
Clinical trial
A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Status: Completed, Estimated PCD: 2019-08-01
Clinical trial
A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Efbemalenograstim
Clinical trial
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Status: Active (not recruiting), Estimated PCD: 2015-02-25
Product
Individual Patient TCR-Transduced PBL
Clinical trial
A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel
Status: Completed, Estimated PCD: 2006-03-09
Product
Custirsen
Drug
docetaxel
Clinical trial
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Brain, Liver, Lung, and Ovarian Cancer Tumors and the Investigation of Its Mechanism of Action
Status: Recruiting, Estimated PCD: 2026-07-01
Product
Propofol
Product
Sevoflurane
Clinical trial
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD According to SmPC
Status: Completed, Estimated PCD: 2022-06-10
Product
Trabectedin + PLD
Clinical trial
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Status: Not yet recruiting, Estimated PCD: 2030-08-30
Product
[68Ga]Ga-EVS459
Clinical trial
Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Status: Terminated, Estimated PCD: 2023-05-31
Clinical trial
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Status: Withdrawn, Estimated PCD: 2022-12-14
Clinical trial
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Product
Enoxaparin
Product
Enoxaparin + Rosuvastatin
Clinical trial
Sorafenib Combined With Carboplatin/Paclitaxel and Sorafenib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer: a Single-arm, Multicenter, Exploratory Clinical Study
Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS)
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2016-05-09
Product
ganetespib
Clinical trial
Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors
Status: , Estimated PCD: 2002-07-01
Clinical trial
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-06-20
Product
TRPV6 Calcium Channel Inhibitor SOR-C13
Clinical trial
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab in Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Product
Fuzuloparib Combination with Bevacizumab
Clinical trial
A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer
Status: Withdrawn, Estimated PCD: 2024-03-08
Clinical trial
Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer Patients
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Loperamide
Clinical trial
Intraperitoneal FATE FT516 and Interleukin-2 (IL-2) With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2022-01-01
Product
IP FT516
Clinical trial
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial
Status: Recruiting, Estimated PCD: 2024-08-10
Clinical trial
NKG2D CAR-NK Cell Therapy for Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-04-01
Product
NKG2D CAR-NK
Clinical trial
Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
Status: Recruiting, Estimated PCD: 2026-04-15
Drug
olaparib
Clinical trial
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
BA3011
Product
BA3021
Product
To be determined
Clinical trial
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)
Status: Not yet recruiting, Estimated PCD: 2028-01-10
Product
Tuvusertib
Product
Lartesertib
Clinical trial
Efficacy and Safety of Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer: a Single-center Prospective Single-arm Study
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Product
Huaier
Clinical trial
Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Status: Terminated, Estimated PCD: 2022-09-01
Clinical trial
A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer
Status: Terminated, Estimated PCD: 2022-07-15
Clinical trial
A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Status: Completed, Estimated PCD: 2020-11-11
Clinical trial
A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
A Non-randomized Control Study Comparing Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
Status: Completed, Estimated PCD: 2019-11-30
Product
Carboplatin/paclitaxel
Clinical trial
Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Liposomal Doxorubicin
Clinical trial
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Bicalutamide
Product
Everolimus
Product
Itraconazole
Clinical trial
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2022-01-19
Product
ARG1-18,19,20
Clinical trial
Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer
Status: Completed, Estimated PCD: 2021-06-15
Clinical trial
T-cell Therapy in Combination With Checkpoint Inhibitors for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2020-06-01
Product
TIL
Drug
Lurbinectedin
Clinical trial
Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Nab-Paclitaxel + Carboplatin
Clinical trial
A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-02-23
Product
Mivavotinib
Clinical trial
Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers
Status: Recruiting, Estimated PCD: 2028-01-04
Product
Hydroxychloroquine
Clinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Ipilimumab + Pembrolizumab + Durvalumab
Clinical trial
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2033-11-01
Clinical trial
An Exploratory Clinical Study of Neoadjuvant Therapy With Pamiparib Combined With Surufatinib for Advanced Ovarian Cancer: A Single-arm, Prospective, Single-center Clinical Study
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-17
Drug
Metformin
Clinical trial
A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Bleomycin
Product
Etoposide
Clinical trial
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Status: Recruiting, Estimated PCD: 2023-09-01
Drug
Defactinib
Clinical trial
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-10
Product
BMS-986340
Clinical trial
Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
Status: Completed, Estimated PCD: 2020-11-19
Product
Trabectedin + Durvalumab
Clinical trial
Real-world Data From a Multi-center Study: Insights to the Effectiveness and Safety in Patients With Ovarian Cancer Receiving Niraparib as First-line Maintenance Therapy
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Status: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazine
Clinical trial
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Ovarian, Fallopian Tube, and Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Microdevice
Clinical trial
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
huCART-meso
Clinical trial
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecific Antibody) Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer: a Single-arm, Open-label, Multicenter Clinical Study
Status: Recruiting, Estimated PCD: 2023-12-01
Product
AK104
Clinical trial
A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Status: Completed, Estimated PCD: 2022-01-18
Clinical trial
Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2025-05-28
Product
Akt/ERK Inhibitor ONC201
Clinical trial
An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors
Status: Withdrawn, Estimated PCD: 2024-09-30
Product
Wee1 Inhibitor ZN-c3
Product
TSC-200-A0201
Product
TSC-204
Product
TSC-204-C0702 + TSC-203-A0201
Clinical trial
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
PHN-010
Clinical trial
An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
DCP-001
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20251
Product
ACR-368
Abstract
https://www.nejm.org/doi/full/10.1056/NEJMoa2309169
Abstract
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5505
Product
paclitaxel + ofranergene obadenovec
Clinical trial
An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian Cancer: a Prospective, Multicenter Clinical Study
Status: Recruiting, Estimated PCD: 2025-05-30
Drug
Varlilumab
Clinical trial
A Phase 2A Multicenter, Open Label Study of Promitil for the Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After First Line Therapy
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Promitil
Clinical trial
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2028-09-01
Product
Bendamustine
Clinical trial
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2028-12-01
Product
Sequencing of DNA, RNA, and Proteins
Clinical trial
A Collaborative Project Aimed to Establish a WGS-based Reference Standard for Evaluating the Analytical Performance of HRD Status Testing
Status: Completed, Estimated PCD: 2023-12-13
Drug
PARPi
Product
P-MUC1C-ALLO1 CAR-T cells
Clinical trial
A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Combination With N-803 (Il-15 Superagonist) in Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Product
Cytokine-Induced Memory-like Natural Killer Cells
Product
IL-15 Superagonist
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
B013
Clinical trial
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
PCR/PCR/LDR Strategy
Clinical trial
A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib as Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
GM-CSF
Product
Dendritic Cell/Tumor Fusion Vaccine
Drug
imiquimod
Clinical trial
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Status: Terminated, Estimated PCD: 2020-09-29
Product
Autologous Monocytes + ACTIMMUNE + SYLATRON
Clinical trial
A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-12
Product
DPX-Survivac
Product
ZEN-3694
Clinical trial
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
N-Acetyl-Cysteine
Clinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Status: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo
Status: Completed, Estimated PCD: 2021-03-31
Product
HER-2/neu Peptide Vaccine
Clinical trial
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)
Status: Not yet recruiting, Estimated PCD: 2027-08-31
Drug
R-CHOP
Clinical trial
A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2018-10-08
Product
Ketorolac
Clinical trial
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Status: Active (not recruiting), Estimated PCD: 2026-10-29
Product
Copanlisib
Drug
fulvestrant
Product
Ixabepilone
Clinical trial
Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer
Status: Completed, Estimated PCD: 2005-05-01
Product
90Y-hu3S193
Product
111In-hu3S193
Clinical trial
Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Completed, Estimated PCD: 2011-01-24
Product
ALVAC-NY-ESO-1-TRICOM vaccine
Clinical trial
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Status: Recruiting, Estimated PCD: 2024-12-27
Product
Young TIL
Drug
Pembrolizumab (Keytruda)
Clinical trial
Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer
Status: Active (not recruiting), Estimated PCD: 2026-12-04
Product
RP-6306
Clinical trial
4FMFES Positron Emission Tomography (PET) for Detection of Newly-diagnosed ER+ Endometrial and Ovarian Cancers
Status: Completed, Estimated PCD: 2023-08-31
Product
hyoscine-n-butylbromide
Clinical trial
Phase l Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Lapatinib and Paclitaxel
Clinical trial
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2027-08-01
Product
Adjuvant Chemotherapy
Clinical trial
A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Completed, Estimated PCD: 2006-05-09
Product
NY-ESO-1
Clinical trial
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Drug
Envafolimab
Clinical trial
A Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2027-05-17
Product
RC48+carboplatin±bevacizumab
Clinical trial
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Blood sample and tissue sample
Clinical trial
Clinical Study of Fluzopalil Combined With Apatinib for Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Apatinib
Clinical trial
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Phase II Investigational Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance
Status: Not yet recruiting, Estimated PCD: 2025-08-30
Clinical trial
A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Autologous Tumor Infiltrating Lymphocytes MDA-TIL
Clinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2024-11-30
Product
Berzosertib
Product
Interleukin-2
Clinical trial
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Placebos
Clinical trial
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
Status: Active (not recruiting), Estimated PCD: 2022-11-10
Product
Blood Samples
Clinical trial
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children
Status: Completed, Estimated PCD: 2015-04-09
Product
Sodium Thiosulfate
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-07
Product
XB002
Clinical trial
Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Status: Not yet recruiting, Estimated PCD: 2026-09-30
Product
Anticoagulant
Clinical trial
Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study
Status: Completed, Estimated PCD: 2021-08-18
Clinical trial
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
Platinum-based Chemotherapy
Clinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-07
Product
Adjuvant chemotherapy
Clinical trial
Phase I Trial to Evaluate Safety and Preliminary Efficacy of CLDN6/GPC3/Mesothelin/AXL-CAR-NK in Patients With CLDN6/GPC3/Mesothelin/AXL-positive Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
Clinical trial
A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Status: Active (not recruiting), Estimated PCD: 2016-03-31
Clinical trial
[68Ga]Ga-FAPI-46 PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients With Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-11-01
Product
68Ga-FAPi-46
Clinical trial
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus
Status: Recruiting, Estimated PCD: 2024-05-01
Drug
Avutometinib
Clinical trial
A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers
Status: Completed, Estimated PCD: 2021-06-29
Product
Ziv-Aflibercept
Product
VX-970
Clinical trial
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Completed, Estimated PCD: 2009-05-01
Product
rV-NY-ESO-1
Product
rF-NY-ESO-1 vaccine
Clinical trial
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
Status: Recruiting, Estimated PCD: 2024-08-31
Product
NX-1607
Clinical trial
Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
Status: Recruiting, Estimated PCD: 2024-12-31
Product
NGS analysis of ctDNA
Clinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Status: Recruiting, Estimated PCD: 2027-12-30
Product
HBI 0201-ESO TCRT
Clinical trial
Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2022-11-28
Product
HER-2 vaccine
Product
Extension HER-2 vaccine
Clinical trial
Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Stealth Liposomal Doxorubicin
Product
Metformin
Drug
placebo
Clinical trial
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Phase I/II Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2026-07-01
Product
TROP2-CAR-NK
Clinical trial
The Effect of Tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Randomized Pilot Study
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Tinzaparin
Clinical trial
A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
Platinum-based Systemic Chemotherapy
Product
Psilocybin
Clinical trial
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2021-02-28
Product
Standard of Care PD-1 Therapy
Product
TSC-204-A0101
Product
TSC-204-A0201 + TSC-204-A0101
Clinical trial
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer - a Pragmatic Trial
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Application of MRD Combined With Personalized Vaccine in the Adjuvant Treatment of Postoperative Recurrence Prevention of Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Neoantigen polypeptide vaccine
Clinical trial
Early-stage Clinical Study of Mesothelin-specific Chimericantigen Receptor T Cells (LD013) in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer
Status: Completed, Estimated PCD: 2023-02-01
Product
Mesothelin-Specific Chimeric Antigen Receptor T Cell Injection
Clinical trial
A PHASE 1-2 NEOADJUVANT DOSE FINDING, SAFETY, AND IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR RECURRENT OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINES
Status: , Estimated PCD: 2025-12-31
Product
Cisplatin + Celecoxib + DC Vaccine
Product
Cisplatin + CKM + Celecoxib + DC Vaccine
Product
LVGN3616
Clinical trial
A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
Status: Completed, Estimated PCD: 2021-09-19
Drug
Tamoxifen
Clinical trial
A Pilot Study to Evaluate the Efficacy and Safety of Preoperative Olaparib Monotherapy and Preoperative Olaparib Plus Pembrolizumab Combination Therapy in Patients With HRD-Positive Stage III or IV Advanced Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2023-06-30
Product
Binimetinib
Clinical trial
IMPACT: A Phase 0 Randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.
Status: Completed, Estimated PCD: 2023-01-05
Drug
Aspirin
Drug
Tucidinostat
Product
Capivasertib
Product
Volrustomig
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-21
Product
CHT101
Clinical trial
A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-05-30
Drug
CUSP06
Clinical trial
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Status: Recruiting, Estimated PCD: 2026-08-31
Product
Hyperpolarized 13-C-pyruvate
Clinical trial
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
BG-68501
Clinical trial
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Status: Completed, Estimated PCD: 2021-03-12
Clinical trial
Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Status: Completed, Estimated PCD: 2015-05-01
Product
vargatef
Clinical trial
Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Status: Completed, Estimated PCD: 2014-10-01
Product
Carboplatin + Liposomal Doxorubicin
Clinical trial
A Phase II Prospective Single-arm Clinical Study of Aribulin Combined With Carboplatin and Bevacizumab in the First-line Treatment of Platinum-sensitive Recurrent Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Product
Aribulin;carboplatin;bevacizumab
Clinical trial
The IIT Study of Evaluation of Platelet-coupled IL-2 Cell Injection (P-IL-2) Single Agent and With Anti-PD-1 Monoclonal Antibody on the Safety, Tolerance and Preliminary Effectiveness in Patients With Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-31
Product
P-IL-2
Product
P-IL-2 plus Anti-PD-1 Monoclonal Antibody
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
Status: Withdrawn, Estimated PCD: 2026-08-01
Product
PiB and DPA-714 PET scan
Clinical trial
The Utility of Circulating Tumor DNA in Monitoring the Response to Pegylated Liposomal Doxorubicin in Platinum-resistant Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2024-04-01
Drug
pegylated liposomal doxorubicin
Clinical trial
Induction of Neo-Antigen Specific Cytotoxic T Cells by Autologous Tumor Lysate-loaded Specialized Cross-Presenting Dendritic Cells in Epithelial Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy, the NEODOC Study
Status: Recruiting, Estimated PCD: 2024-10-01
Product
XP-DC vaccinations
Clinical trial
A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Product
ARM A Durvalumab/chemotherapy association
Product
ARM B Durvalumab + Tremelimumab + Chemotherapy
Clinical trial
An Observational Study to Evaluate the Safety of the Combination Therapy of Genexol PM and Carboplatin as First-line Therapy for Ovarian Cancer Patients
Status: Completed, Estimated PCD: 2022-04-30
Product
Genexl PM
Clinical trial
Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Tislelizumab
Clinical trial
A Phase I Trial of the Combination of Olaparib and Navitoclax in Women With High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-04-28
Product
Navitoclax
Clinical trial
Safety and Efficacy of High Dose Inorganic seLenium for Preventing Chemotherapy Induced pEripheral Neuropathy in platINUM Sensitive Recurrent Ovarian, Fallopian, Primary Peritoneal Cancer: Phase III Randomised Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2023-04-30
Product
Sodium Selenite
Clinical trial
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2028-02-09
Clinical trial
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors
Status: Terminated, Estimated PCD: 2024-05-22
Product
TNG348
Clinical trial
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy: a Multi-center Prospective Randomized Controlled Trial.
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Product
Sodium Sulfate
Drug
Selinexor
Clinical trial
Phase I/II Study to Test the Immunogenicity, Feasibility, and Safety of Autologous PEP-DC Vaccine vs. Autologous OC-DC Vaccine Followed by PEP-DC Vaccine, in Combination With Low-dose Cyclophosphamide, in Patients With Advanced HGSOC
Status: Not yet recruiting, Estimated PCD: 2030-03-01
Product
PEP-DC1
Product
OC-DC
Product
PEP-DC2
Product
Tolinapant
Clinical trial
Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2011-04-21
Product
celecoxib
Product
iC9-CAR.B7-H3 T cells
Product
[177Lu]Lu-EVS459
Clinical trial
Efficacy and Safety of Huaier Granule in Combination With Nilaparil in First-line Maintenance Therapy in Postoperative Patients With Stage III/IV BRCA Wild-type Ovarian Cancer: a Single-center Prospective, Single-arm Study
Status: Not yet recruiting, Estimated PCD: 2023-12-01
Clinical trial
Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
Status: Terminated, Estimated PCD: 2018-04-01
Product
BRCA genetic data
Product
Sleeping Beauty Transposed
Clinical trial
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2038-09-01
Drug
VCN-01
Clinical trial
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy
Status: Terminated, Estimated PCD: 2021-08-18
Product
Nicotinamide Riboside
Clinical trial
A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
Status: Completed, Estimated PCD: 2023-04-06
Product
WT1
Clinical trial
A Single-Center, Open-Label, Single-Arm, Phase I Study With Dose Expansion Cohort of Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-07
Product
Sacituzumab
Clinical trial
A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study
Status: Recruiting, Estimated PCD: 2024-08-01
Product
NY-ESO-1 Vaccine
Clinical trial
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g
Status: Completed, Estimated PCD: 2014-05-01
Product
89Zr-MMOT0530A
Clinical trial
Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study
Status: Recruiting, Estimated PCD: 2025-06-17
Product
Propranolol
Clinical trial
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-06-30
Product
PARP inhibitor
Clinical trial
A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Completed, Estimated PCD: 2021-06-01
Clinical trial
Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Etodolac
Clinical trial
A Phase I Trial of Intraperitoneal LSTA1 in Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy
Status: Recruiting, Estimated PCD: 2028-12-01
Product
CRS-HIPEC + LSTA1
Clinical trial
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-12-21
Product
ACE-86225106
Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001
Clinical trial
An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-03-11
Clinical trial
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ETX-19477
Drug
Devimistat
Drug
5-FU
Clinical trial
Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy
Status: Terminated, Estimated PCD: 2023-06-26
Product
W_ova1
Clinical trial
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Status: Completed, Estimated PCD: 2020-08-20
Product
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Clinical trial
Phase 1B Trial With Unesbulin in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells
Status: Completed, Estimated PCD: 2021-08-11
Product
Unesbulin
Clinical trial
An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib Since at Least 6 Months
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
3 cycles chemotherapy
Product
6 cycles chemotherapy
Clinical trial
SPECT Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 in Lung and Ovarian Cancers Patients
Status: , Estimated PCD: 2024-12-31
Product
[123I]I-DARPIN-Ec1
Clinical trial
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
Status: Recruiting, Estimated PCD: 2023-12-15
Drug
Docetaxel
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers
Status: Recruiting, Estimated PCD: 2027-01-01
Product
Anti-hCD70 CAR transduced PBL
Clinical trial
A Study of Serum Folate Levels in Patients Treated With Olaparib
Status: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Folic Acid
Clinical trial
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase I/II Trial of Intraperitoneal (IP) Cisplatin Combined With IV Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Their Initial Surgery Performed Following Neoadjuvant Intravenous Chemotherapy
Status: Terminated, Estimated PCD: 2009-07-01
Clinical trial
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
XmAb®808
Product
Keytruda
Clinical trial
A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-01
Product
SON-DP
Clinical trial
Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2026-11-01
Product
DOXIL
Product
Withaferin A
Product
Ashwagandha
Product
Combination of ASWD and DOXIL
Clinical trial
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031
Clinical trial
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-11-01
Product
SGN-MesoC2
Clinical trial
A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Not yet recruiting, Estimated PCD: 2028-07-31
Clinical trial
A Pragmatic Randomized Phase III Trial to Assess the Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Product
Autologous MUC1-activated T-cells
Clinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Anlotinib
Product
Carboplatin + Paclitaxel